Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

Eligible subjects will sign a consent form and have blood drawn at approximately 8-17 weeks
gestation. Subjects will received $200 reimbursement for providing this blood sample. The
collected samples will be used to help develop non-invasive prenatal diagnostic testing
using Natera's Parental Support technology which is already commercialized for genetic
diagnosis of in-vitro embryos. In this study, the technology will be tested for it's ability
to analyze fetal-specific pieces of DNA isolated from the mother's blood. No results of the
maternal blood testing will be reported to the subject or to their physicians.

Inclusion Criteria:

- Pregnant women willing to donate a blood sample during the first or second trimester
of their pregnancy (approximately 8-17 weeks gestation)

- Use of Natera (formerly Gene Security Network)'s commercial preimplantation genetic
testing (PGS/PGD)to achieve the current pregnancy

Exclusion Criteria:

- Pregnant women who did not use Natera (formerly Gene Security Network)'s PGS/PGD
testing to achieve their current pregnancy